🇺🇸 FDA

Company profile · Sponsor

Arcutis

Arcutis Biotherapeutics

ARQT · NYSE pharma WESTLAKE VILLAGE, CA, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

Arcutis (ARQT) is a pharma company. headquartered in WESTLAKE VILLAGE, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker ARQT
Exchange NYSE
Company type pharma
Headquarters WESTLAKE VILLAGE, CA, USA
SEC CIK 0001787306

Pipeline (24)

Search pipeline →

  1. ARQ-151 0.3% cream

    Arcutis

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  2. ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

    Arcutis

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  3. Roflumilast 0.3% cream

    Arcutis

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  4. Roflumilast Cream

    Arcutis

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  5. Roflumilast Cream 0.05%

    Arcutis

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  6. Roflumilast Cream 0.15%

    Arcutis

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  7. Roflumilast Foam

    Arcutis

    Seborrheic Dermatitis

    phase 3 small molecule completed

    1 trial

  8. Roflumilast Foam 0.3%

    Arcutis

    Scalp Psoriasis

    phase 3 small molecule completed

    1 trial

  9. Topical roflumilast

    Arcutis

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  10. ARQ-151 cream 0.05%

    Arcutis

    Atopic Dermatitis (Eczema)

    phase 2 small molecule completed

    1 trial

  11. ARQ-151 cream 0.3%

    Arcutis

    Psoriasis

    phase 2 small molecule completed

    2 trials

  12. ARQ-151 cream 0.5%

    Arcutis

    Psoriasis

    phase 2 small molecule completed

    1 trial

  13. ARQ-154

    Arcutis

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial

  14. ARQ-252 cream 0.3%

    Arcutis

    Chronic Hand Eczema

    phase 2 small molecule completed

    1 trial

  15. ARQ-252 cream 0.3%

    Arcutis

    Vitiligo

    phase 2 small molecule terminated

    1 trial

  16. Roflumilast

    Arcutis

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  17. Roflumilast Cream 0.05%

    Arcutis

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  18. Roflumilast Cream 0.3%

    Arcutis

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  19. Roflumilast Foam 0.3%

    Arcutis

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial

  20. Roflumilast foam 0.3%

    Arcutis

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  21. Roflumilast topical 0.3% foam

    Arcutis

    Non-segmental Vitiligo

    phase 2 small molecule active

    1 trial

  22. Topical roflumilast 0.3% foam

    Arcutis

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  23. ARQ-151 cream 0.15%

    Arcutis

    Atopic Dermatitis (Eczema)

    phase 1 small molecule completed

    1 trial

  24. ARQ-151- cream 0.3%

    Arcutis

    Plaque Psoriasis

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. roflumilast

    DAXAS

    TOPICAL approved

    R03DX07

Patents (8)

Search patents →

  1. US 12390453

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12336983

    Inhibition of crystal growth of roflumilast

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12329751

    Topical roflumilast formulation having antifungal properties

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12310956

    Topical roflumilast formulation having improved delivery and plasma half-life

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12257242

    Inhibition of crystal growth of roflumilast

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12220409

    Roflumilast formulations with an improved pharmacokinetic profile

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12161643

    Stable formulations of SHR0302

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12144802

    Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Arcutis?

Arcutis (ARQT) is a pharma company. headquartered in WESTLAKE VILLAGE, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Arcutis sponsor?

We track 24 ClinicalTrials.gov-linked programs for Arcutis, including ARQ-151 0.3% cream and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Arcutis company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.